PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 1, 2021Neuro-Oncology2,604 citationsOpen Access

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018

View Full Paper
QOQuinn T. OstromGCGino CioffiKWKristin Waite

Key Points

  • To provide comprehensive, population-based incidence, mortality, and survival statistics for primary brain and other central nervous system (CNS) tumors diagnosed in the United States from 2014 to 2018.
  • Analyzed national population-based cancer registry data from CBTRUS, CDC, and NCI covering the entire US population from 2014 to 2018.
  • Calculated average annual age-adjusted incidence rates (AAAIR) and mortality rates per 100,000 using the 2000 US standard population, alongside five-year relative survival rates.
  • The overall AAAIR for all primary CNS tumors was 24.25 per 100,000 (malignant: 7.06; non-malignant: 17.18), with higher incidence in females (26.95 vs. 21.35) and non-Hispanics (24.68 vs. 22.12).
  • Glioblastoma was the most frequent malignant tumor (14.3% of all tumors; 49.1% of malignant) occurring predominantly in males, while meningioma was the most common non-malignant tumor (39.0% of all tumors; 54.5% of non-malignant) occurring predominantly in females.
  • Five-year relative survival was 35.6% for malignant CNS tumors (average annual mortality rate: 4.43 per 100,000) compared to 91.8% for non-malignant CNS tumors.

Abstract

Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest population-based cancer registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy and is the first CBTRUS Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.25 (Malignant AAAIR=7.06, Non-malignant AAAIR=17.18). This overall rate was higher in females compared to males (26.95 versus 21.35) and non-Hispanics compared to Hispanics (24.68 versus 22.12). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.3% of all tumors and 49.1% of malignant tumors), and the most common non-malignant tumor was meningioma (39.0% of all tumors and 54.5% of non-malignant tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0–19 years), the incidence rate of all primary brain and other CNS tumors was 6.21. An estimated 88,190 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2021 (25,690 malignant and 62,500 non-malignant). There were 83,029 deaths attributed to malignant brain and other CNS tumors between 2014 and 2018. This represents an average annual mortality rate of 4.43 per 100,000 and an average of 16,606 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.6%, for a non-malignant brain and other CNS tumors the five-year relative survival rate was 91.8%.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ostrom et al. (2021) studied this question.

synapsesocial.com/papers/69d733a65f9a1dad5348f457https://doi.org/10.1093/neuonc/noab200
Ask AI
Helpful
Bookmark
Share
View Full Paper